University Hospital Tuebingen’s New Trial Tests CD19 CAR T-Cell Therapy for Autoimmune Diseases
The Phase 1/2 study will assess the safety of UKT-CART19.1 in an estimated 36 patients with relapsed or refractory autoimmune diseases.

University Hospital Tuebingen is sponsoring a Phase 1/2 study of UKT-CART19.1, a CD19-targeted CAR T-cell therapy, in people whose autoimmune diseases have returned or have not responded to treatment. The study plans to enroll 36 participants across several autoimmune conditions at a single center.
All participants will receive the study therapy. The primary assessment follows safety over six months and includes serious adverse events, infusion reactions, and selected events during the first 28 days after treatment.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
- Sponsor: University Hospital Tuebingen, Germany
- Phase/Status: Phase 1/2, not yet recruiting
- Indication: Relapsed/refractory autoimmune diseases, including pemphigus vulgaris, ANCA associated vasculitis, rheumatoid arthritis, IIM, multiple sclerosis, immune thrombocytopenic purpura, and systemic sclerosis; planned enrollment 36
- Arms/Dosing: CAR-T cells targeting CD19 (UKT-CART19.1), single dose containing 1.0×10^6 CAR+ cells per kg body weight
- Control: None
- Endpoints: Primary endpoint: Safety of UKT-CART19.1 in relapsed/refractory autoimmune diseases at month 6, measured by number of serious adverse events, adverse events of special interest within first 28 days after CAR T cell infusion (CTCAE v6.0), non-relapse mortality at day 28, and acute infusional toxicity; timeframe: 6 months
- Timing: Study start: January 2027 (estimated); primary completion: June 2028 (estimated); study completion: September 2028 (estimated)
- Contact: Ann-Christin Pecher, PD Dr. med., ann-christin.pecher@med.uni-tuebingen.de, +49 07071 29-8409
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Kyverna Therapeutics Reports One-Year Phase 2 Results for CAR T-Cell Therapy in Stiff Person Syndrome
Fate Therapeutics Presents Updated Preliminary Data on iPSC-Derived CAR-T for Active Lupus Nephritis
FDA Clears AbelZeta’s CAR-T Trial for Progressive MS
Fate Therapeutics Launches CAR T Trial for Lupus Nephritis
CREATE Medicines to Launch First Phase 1/2 In Vivo Trial of CAR-T Candidate CRT-402 for Autoimmune Diseases in Australia
Sonoma Biotherapeutics to Automate its Treg Cell Manufacturing Using Cellares’ Cell Shuttle Platform
IN8bio Reports Median Overall Survival of 20.9 Months in Newly Diagnosed Glioblastoma Patients Receiving Repeat-Dose Gamma-Delta T Cell Therapy
UConn Health Launches CAR-T Cell Therapy Program for Blood Cancers







